Ernexa Therapeutics Inc. (ERNA) Liabilities and Shareholders Equity (2010 - 2026)

Ernexa Therapeutics (ERNA) has 17 years of Liabilities and Shareholders Equity data on file, last reported at $10.5 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 108.4% year-over-year to $10.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $30.1 million (down 53.31% YoY) and the FY2025 annual result came in at $5.8 million, up 10.72% from the prior year.
• Liabilities and Shareholders Equity climbed to $10.5 million in Q1 2026, from $5.8 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $52.2 million in Q3 2023 to a low of $5.1 million in Q1 2025.
• A 5-year average of $24.3 million and a median of $20.9 million in 2022 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity surged 228.68% — and 2025, when it plunged 89.81%.
• Tracing ERNA's Liabilities and Shareholders Equity over 5 years: stood at $22.3 million in 2022, then surged by 120.53% to $49.1 million in 2023, then slumped by 89.28% to $5.3 million in 2024, then grew by 10.72% to $5.8 million in 2025, then soared by 80.72% to $10.5 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $10.5 million (Q1 2026), $5.8 million (Q4 2025), and $6.2 million (Q3 2025), per Business Quant data.